Supercharged donor cells take on lymphoma in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis and clinical course falling into one of the following categories: 1. Hodgkin lymphoma 2. CD30+ aggressive B-cell lymphoma 3. ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma 4. ALK-positive anaplastic T cell lymphoma 2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory. 3. Age 12 to 75. 4. Bilirubin less than or equal to 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin less than or equal to 3 times the upper limit of normal). 5. AST less than 3 times the upper limit of normal. 6. Estimated GFR \> 70 mL/min. 7. Pulse oximetry of \> 90% on room air 8. Karnofsky or Lansky score of \> 60%. 9. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy. 10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom. 11. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form. Exclusion Criteria: 1. Received an investigational cell therapy or vaccine within the past 6 weeks. 2. Received an investigational small molecule drug within the past 2 weeks. 3. Received anti-CD30 antibody-based therapy within the previous 4 weeks. 4. History of hypersensitivity reactions to murine protein-containing products. 5. Pregnant or lactating. 6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion). 7. Current use of systemic corticosteroids at a dose equivalent to or higher than 10 mg/day of prednisone. 8. Active significant, uncontrolled bacterial, viral or fungal infection. 9. Symptomatic cardiac disease (NYHA Class III or IV disease).